Rigel Pharmaceuticals, Inc. (RIGL) News
Filter RIGL News Items
RIGL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RIGL News Highlights
- For RIGL, its 30 day story count is now at 3.
- Over the past 1 day, the trend for RIGL's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- ITP are the most mentioned tickers in articles about RIGL.
Latest RIGL News From Around the Web
Below are the latest news stories about RIGEL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RIGL as an investment opportunity.
Q2 2023 Rigel Pharmaceuticals Inc Earnings CallQ2 2023 Rigel Pharmaceuticals Inc Earnings Call |
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue EstimatesRigel (RIGL) delivered earnings and revenue surprises of 50% and 3.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Rigel Reports Second Quarter 2023 Financial Results and Provides Business UpdateRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2023, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment and sales of REZLIDHIA® (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitr |
3 Stocks to Buy for Lottery Jackpot Style ReturnsAlthough you can try your hand at the lottery, your odds of success are probably far better with stocks with high returns. |
Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business UpdateRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2023 financial results after market close on Tuesday, August 1, 2023. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business. |
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 247,400 stock options to six non-executive employees vesting over four years with a one-year cliff. |
Investors in Rigel Pharmaceuticals (NASDAQ:RIGL) have unfortunately lost 55% over the last five yearsWe think intelligent long term investing is the way to go. But no-one is immune from buying too high. Zooming in on an... |
Bullish Rigel Pharmaceuticals Insiders Rewarded As Their Investment Rises To US$1.5m \Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) insiders who bought shares over the past year were rewarded handsomely last... |
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AMLRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens. The data are being presented in a poster at the EHA2023 Hybrid Congress. |
Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood AdvancesRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an expert review article in Blood Advances examining the development path and positioning of REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in the mIDH1 relapsed/refractory (R/R) acute myeloid leukemia (AML) treatment landscape. |